Ionis Pharmaceuticals reported positive Phase 3 trial data for its antisense oligonucleotide targeting mobility stabilization in Alexander disease, a rare and often fatal neurological disorder. Following this milestone, Ionis plans to submit a request for FDA approval. The data mark a significant step towards offering the first disease-modifying treatment for this underserved patient population, demonstrating the growing role of antisense therapy in rare neurological conditions.